4SC AG
Clinical Trials
47
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (37 trials with phase data)• Click on a phase to view related trials
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
- Conditions
- Cutaneous T Cell LymphomaSezary SyndromeMycosis Fungoides
- Interventions
- Drug: [14C]-resminostat
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- 4SC AG
- Target Recruit Count
- 5
- Registration Number
- NCT04955340
- Locations
- 🇬🇧
Covance Clinical research Unit Ltd., Leeds, United Kingdom
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
- Conditions
- Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- 4SC AG
- Registration Number
- NCT04874831
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
- Conditions
- Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- 4SC AG
- Target Recruit Count
- 19
- Registration Number
- NCT04393753
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇫🇷Bordeaux Hôpital Saint Andre, Bordeaux, France
🇫🇷Hôpital Ambroise Paré - Boulogne-Billancourt, Boulogne-Billancourt, France
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- 4SC AG
- Target Recruit Count
- 40
- Registration Number
- NCT03278665
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Germany
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
- Conditions
- Sezary SyndromeLymphoma, T-Cell, CutaneousMycosis Fungoides
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- 4SC AG
- Target Recruit Count
- 201
- Registration Number
- NCT02953301
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Austria
🇦🇹Medizinische Universität Wien, Wien, Austria
🇧🇪Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
- Prev
- 1
- 2
- 3
- Next
News
4SC AG's Resminostat Faces EMA Review Amidst Financial Constraints
4SC AG has filed for marketing authorization of Resminostat with the EMA for advanced cutaneous T-cell lymphoma, marking a key regulatory milestone.
4SC AG Receives MHRA Waiver for Resminostat in Pediatric CTCL
4SC AG secured a Paediatric Investigation Plan (PIP) waiver from the UK MHRA for resminostat (Kinselby) in advanced-stage cutaneous T-cell lymphoma (CTCL).
Resminostat Receives European Orphan Drug Designation for Cutaneous T-Cell Lymphoma
Resminostat, developed by 4SC AG, has been granted Orphan Drug Designation by the EMA for treating cutaneous T-cell lymphoma (CTCL).
Resminostat Shows Promise in Advanced Cancers: Clinical Updates and Biomarker Identification
Resminostat combined with FOLFIRI chemotherapy demonstrates a manageable safety profile and encouraging clinical activity in patients with advanced, KRAS-mutant colorectal cancer (CRC).